Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, ...

At the 2025 ASCO (American Society of Clinical Oncology) Annual Meeting, Dr. Armenian presented findings from the session ...

With the American Society of Clinical Oncology (ASCO) annual meeting in full swing at Chicago’s McCormick Place this past ...

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase ...

Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50.